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Background: The hardware and software differences between MR vendors and individual sites influence the quantification of MR 
spectroscopy data. An analysis of a large data set may help to better understand sources of the total variance in quantified metabo-
lite levels.
Purpose: To compare multisite quantitative brain MR spectroscopy data acquired in healthy participants at 26 sites by using the 
vendor-supplied single-voxel point-resolved spectroscopy (PRESS) sequence.
Materials and Methods: An MR spectroscopy protocol to acquire short-echo-time PRESS data from the midparietal region of the brain 
was disseminated to 26 research sites operating 3.0-T MR scanners from three different vendors. In this prospective study, healthy 
participants were scanned between July 2016 and December 2017. Data were analyzed by using software with simulated basis sets 
customized for each vendor implementation. The proportion of total variance attributed to vendor-, site-, and participant-related 
effects was estimated by using a linear mixed-effects model. P values were derived through parametric bootstrapping of the linear 
mixed-effects models (denoted Pboot).
Results: In total, 296 participants (mean age, 26 years 6 4.6; 155 women and 141 men) were scanned. Good-quality data were 
recorded from all sites, as evidenced by a consistent linewidth of N-acetylaspartate (range, 4.4–5.0 Hz), signal-to-noise ratio (range, 
174–289), and low Cramér-Rao lower bounds (5%) for all of the major metabolites. Among the major metabolites, no vendor ef-
fects were found for levels of myo-inositol (Pboot . .90), N-acetylaspartate and N-acetylaspartylglutamate (Pboot = .13), or glutamate 
and glutamine (Pboot = .11). Among the smaller resonances, no vendor effects were found for ascorbate (Pboot = .08), aspartate (Pboot 
. .90), glutathione (Pboot . .90), or lactate (Pboot = .28).
Conclusion: Multisite multivendor single-voxel MR spectroscopy studies performed at 3.0 T can yield results that are coherent across 
vendors, provided that vendor differences in pulse sequence implementation are accounted for in data analysis. However, the site-
related effects on variability were more profound and suggest the need for further standardization of spectroscopic protocols.
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Single-voxel proton (hydrogen 1 [
1H]) MR spectroscopy gives 
useful information for both clinical diagnosis and research 
studies (1,2) and is commercially available with most MRI 
scanners at 1.5 T and 3.0 T. The point-resolved spectroscopy 
(PRESS) sequence (3) is most widely used for brain MR spec-
troscopy because it provides robust results from well-defined 
regions of interest. However, implementations of the sequence 
are diverse among manufacturers and research sites. They dif-
fer in terms of timing and waveforms of the radiofrequency 
pulses, as well as water suppression and preparation methods, 
all of which may influence quantification. While recent efforts 
have focused on standardization of single-voxel MR spectros-
copy methods between vendors, including the use of advanced 
localization sequences such as semi-localized by adiabatic selec-
tive refocusing (4,5), currently most clinical MR spectroscopy 
studies continue to use the manufacturer-supplied PRESS 
sequence.
At 3.0 T, conventional MR spectroscopy can reliably detect 
the signals of N-acetylaspartate (NAA) and N-acetylaspartylglu-
tamate (total NAA), total choline (glycerophosphocholine and 
phosphocholine), total creatine (tCr) (creatine and phosphocre-
atine), myo-inositol (mI), and glutamate and glutamine (Glx). 
These metabolites are commonly known as major metabolites. 
In addition, a variable number of less abundant minor metabo-
lites are often reported, based on the spectral quality and the 
defined exclusion criteria.
Recently, a large study involving almost 300 healthy partici-
pants at multiple sites was performed, investigating the reliability 
of the measurement of brain g-aminobutyric acid levels by us-
ing the Mescher-Garwood (MEGA)-PRESS (6) spectral editing 
technique (7,8). As a second part of that study, conventional 
short-echo-time MR spectroscopy data were also collected by 
using the vendor-supplied PRESS sequence. The current study 
reports on the results of the analysis of these single-voxel PRESS 
data, which could have important implications for the design of 
multisite studies using MR spectroscopy as an outcome measure, 
as well as for comparing clinical or research results in individual 
participants performed with different scanners.
The purpose of our study, therefore, was to compare multi-
site quantitative brain MR spectroscopy data acquired in healthy 




All data in our prospective study were acquired between July 
2016 and December 2017. Institutional review board approval 
and participant written informed consent were obtained at 
each site. Participants were recruited with the following inclu-
sion criteria: age between 18–35 years, no known neurologic 
illness, and medication free without usage of over-the-counter 
pain relievers or allergy medication in the preceding 36 hours. 
Anonymized data were analyzed at the Johns Hopkins Univer-
sity (Baltimore, Md). As stated previously, participants’ brain 
g-aminobutyric acid levels recorded by using a spectral editing 
sequence were previously reported in the literature (7,8). This 
study reports levels of metabolites collected by using conven-
tional PRESS sequence.
Data Acquisition
Each site acquired vendor-specific 1H MR spectroscopy PRESS 
data with a 3.0-T scanner using phased-array radiofrequency 
head coils. Eight sites were equipped with GE scanners (GE 
Healthcare, Chicago, Ill), 10 with Philips scanners (Philips 
Healthcare, Best, the Netherlands), and eight with Siemens 
scanners (Siemens Healthineers, Erlangen, Germany) (Table 
E1 [online]). Three-dimensional T1-weighted images were ac-
quired to position a 30 3 30 3 30 mm3 MR spectroscopy 
voxel in the medial parietal lobe (Fig 1). The 1H MR spec-
troscopy data were measured with the following parameters: 
repetition time, 2000 msec; echo time, 35 msec; number of 
averages, 64; spectral bandwidth, 2 kHz or 4 kHz or 5 kHz; 
data points, 2048 or 4096; scan time, 2 minutes 8 seconds. 
Water reference scans were acquired for coil combination and 
eddy current correction with similar parameters and 8 or 16 
averages. No other MR acquisition parameters were specified 
to participating sites. Therefore, additional acquisition-related 
methodology including the methods for main magnetic field 
(B0) homogeneity adjustment, phase cycling scheme, water 
suppression, and outer volume suppression varied from site to 
site according to local preferences and availability. The 1H MR 
spectroscopy data were saved as P-files (GE), SDAT/SPAR files 
Abbreviations
CRLB = Cramér-Rao lower bounds, Glx = glutamate and glutamine, 
mI = myo-inositol, NAA = N-acetylaspartate, PRESS = point-resolved 
spectroscopy, SNR = signal-to-noise ratio, tCr = total creatine
Summary
In a multisite study of brain MR spectroscopy performed at 26 sites, 
interindividual differences were found as the main contributor to 
variability, demonstrating that appropriately analyzed MR spectros-
copy data acquired at different sites and with different scanners can 
be compared.
Key Results
 n Short-echo-time MR spectroscopy of the human brain performed 
at 3.0 T quantifies eight metabolites (N-acetylaspartate and 
N-acetylaspartylglutamate [total NAA], glycerophosphocholine and 
phosphocholine, creatine and phosphocreatine, myo-inositol [mI], 
glutamate and glutamine [Glx], glucose and taurine, gluthathione, 
aspartate) in all participants based on the defined quality exclusion cri-
teria in a 27-mL voxel and approximately 2-minute acquisition time.
 n All MR spectra showed a consistent linewidth of N-acetylaspartate 
(range, 4.4–5.0 Hz), signal-to-noise ratio (range, 174–289), and 
low Cramér-Rao lower bounds (5%) for total NAA, glycerophos-
phocholine and phosphocholine, creatine and phosphocreatine, mI, 
and Glx.
 n The vendor contribution to total variance of metabolite levels 
ranged from 0% to 27%. P values were derived through parametric 
bootstrapping of the linear mixed-effects models (denoted as Pboot). 
No vendor effects were found for levels of mI (Pboot . .90), total 
NAA (Pboot = .13), Glx (Pboot = .11), ascorbate (Pboot = .08), aspartate 
(Pboot . .90), glutathione (Pboot . .90), and lactate (Pboot = .28). The 
site-related effects ranged from 3% up to 44% and the remaining 
50%–83% of the total variance was accounted for by interindividual 
differences, which included both actual biologic differences as well 
as within-participant measurement error.
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was fitted to calculate variance partition coefficients to esti-
mate the proportion of total variance attributed to vendor-, 
site-, and participant-related effects. Secondary, conditional 
(Philips), or TWIX files (Sie-
mens). An overview of hard-
ware and software parameters is 
provided in Table E1 (online).
Data Quantification
Data were processed by a medi-
cal physicist (M.P., with 7 years 
of experience) by using auto-
mated in-house Matlab-based 
(MathWorks, Natick, Mass) 
software (9) with the FID-
A toolkit (10). Results were 
evaluated in consensus with all 
coauthors. Raw data (GE and Siemens) were coil combined us-
ing water reference (11) and eddy current corrected, frequency 
corrected, and phase corrected (12). Subsequently, spectra 
were quantified by using LCModel (version 6.3–0D; Stephen 
Provencher, Oakville, Canada) (13) over the frequency range 
from 0.5 ppm to 4.0 ppm. Basis sets consisted of 19 metabo-
lites: alanine, ascorbate, aspartate, creatine, g-aminobutyric 
acid, glucose, glutamine, glutamate, glutathione, glycerophos-
phocholine, lactate, mI, NAA, N-acetylaspartylglutamate, 
phosphocholine, phosphocreatine, phosphoethanolamine, 
scyllo-inositol, and taurine. Metabolite basis spectra were gen-
erated by using custom-built fully localized two-dimensional 
density matrix simulations and vendor-native shaped refocus-
ing pulse information and phase cycling (14). Chemical shifts 
and scalar coupling (J) constants from Tkáč et al (15) were used 
for all metabolites except for NAA, N-acetylaspartylglutamate, 
glutamate, and glutamine, which used values from Govind and 
colleagues (16). Macromolecules were modeled in LCModel 
(Appendix E1 [online]). Four vendor-specific basis sets were 
used to fit the data (two for GE [due to different sequence tim-
ings], one for Philips, and one for Siemens).
All spectra were visually inspected to detect any spurious ar-
tifacts or lipid contamination. A spectrum was excluded from 
further analysis if the lipid peak amplitude was higher than the 
amplitude of the NAA singlet (-CH3 group at 2.008 ppm).
Quantified values were processed based on quality criteria as 
described by Tkáč and colleagues (17). Metabolite values with 
Cramér-Rao lower bounds (CRLB) above 100% were excluded. 
If a specific metabolite did not have CRLBs less than 100% in 
at least 50% (147 of 293) of the quantified spectra, then it was 
excluded from further analysis. Finally, a metabolite was also 
excluded if it had average CRLBs higher than 50%. Signal-to-
noise ratio (SNR) was calculated as a ratio of NAA signal in-
tensity divided by a standard deviation of noise. Linewidth was 
calculated as a full width at half maximum of the NAA peak.
The relative concentration of metabolites was calculated as a 
ratio to tCr.
Statistical Analysis
Linear mixed-effects models were fit to the metabolite data in 
R (version 3.5.3; R Foundation, Vienna, Austria [18]) (M.M. 
[neuroscientist with 12 years of experience with statistics]). 
An unconditional model (Equation 1 in Mikkelsen et al [7]) 
Figure 1: Image shows example of 30 3 30 3 30 mm3 spectroscopic voxel placement on T1-weighted image. Voxel 
was rotated in sagittal plane to be parallel with line connecting genu and splenium of corpus callosum. L = left, R = right.
Participant Demographic Data by Site
Site Identifier Sample Size Age (y)* Sex†
G1 12 23.9 6 4.8 7/5
G2 12 26.8 6 4.0 6/6
G3 7 23.4 6 5.5 2/5
G4 12 25.6 6 4.5 6/6
G5 12 25.5 6 3.7 5/7
G6 12 24.3 6 4.2 6/6
G7 12 28.1 6 4.0 6/6
G8 12 29.7 6 2.1 6/6
All GE 91 26.1 6 4.4 44/47
 P1 12 25.1 6 3.2 6/6
 P2 12 28.8 6 3.9 10/2
 P3 12 29.3 6 3.1 5/7
 P4 12 24.9 6 4.3 7/5
 P5 8 23.1 6 2.4 3/5
 P6 12 27.3 6 3.7 7/5
 P7 12 23.3 6 2.0 6/6
 P8 12 23.6 6 3.7 5/7
 P9 12 25.8 6 4.6 6/6
 P10 12 25.1 6 2.9 6/6
All Philips 116 25.7 6 4.0 61/55
 S1 12 25.7 6 3.7 6/6
 S2 5 40.4 6 7.4 0/5
 S3 12 31.6 6 3.4 9/3
 S4 12 27.7 6 2.8 6/6
 S5 12 26.5 6 3.7 6/6
 S6 12 24.9 6 2.0 6/6
 S7 12 28.8 6 3.8 6/6
 S8 12 24.0 6 3.5 11/1
All Siemens 89 27.8 6 5.2 50/39
Total 296 26.4  6 4.6 155/141
Note.—GX = GE Healthcare (Chicago, IL) sites, PX = Philips 
Healthcare (Best, the Netherlands) sites, SX = Siemens Health-
ineers (Erlangen, Germany) sites.
* Data are means 6 standard deviation.
† Numerators are the number of women, and denominators are 
the number of men.
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Data Quantification
Mean PRESS spectra are displayed in Figure 2, A–C, for each 
vendor. Qualitatively, spectral profiles were in very good agree-
ment across vendors. The creatine and phosphocreatine peak of 
3.9 ppm was consistently lower for data acquired by using GE 
scanners compared with the other two vendors due to higher 
bandwidth of the water suppression pulses (Figure 2, A–C; 
dashed line). Figure 2, D–F, shows vendor-specific mean fits 
and residuals from the LCModel fitting routine. An example 
of a quantified spectrum with fitted basis spectra of metabolites 
and macromolecules is shown in Figure 3.
The overall high quality of the data is reflected in high SNR 
and narrow linewidth values. Vendor-specific mean SNR 6 
standard deviation for GE, Philips, and Siemens scanners were 
174.3 6 37.4, 196.3 6 52.9, and 288.8 6 80.6, respectively. 
Vendor-specific mean linewidth of NAA for GE, Philips, and 
Siemens was 5.0 Hz 6 0.8, 4.6 Hz 6 1.0, and 4.4 Hz 6 0.6, 
respectively. The individual site and vendor SNR and linewidth 
values are shown in Figure E1 (online). SNR values of data ac-
quired by using Siemens scanners was higher than were SNR 
values acquired by using GE and Philips scanners (both PHolm , 
.001). SNR values were not different between data acquired by 
using GE and Philips scanners (PHolm = .35). There were no dif-
ferences in linewidth between the data acquired by using scan-
ners from the different vendors: GE versus Philips, PHolm = .29; 
GE versus Siemens, PHolm = .06; Philips versus Siemens, PHolm = 
.32.
Based on the correlation matrix provided by LCModel (ie, 
mean correlation coefficient for a metabolite pair less than 
−0.3), sums of metabolites are reported for total NAA, tCr 
(creatine and phosphocreatine), glycerophosphocholine and 
linear mixed-effects models (Equation 5 in Mikkelsen et al 
[7]) were also fitted to assess the impact of SNR, linewidth, 
age, and sex on quantified measurements. Goodness of fit was 
calculated as a log-likelihood statistic. Parametric bootstrap-
ping was then used whereby the null distributions of each test 
was simulated by bootstrapping the fitted distributions (2000 
simulations) to evaluate the probability of observing the test 
statistics given the distribution of the null hypotheses (19). P 
values are denoted Pboot.
Effects that were tested included vendor and site, SNR and 
linewidth, and age and sex. Posthoc pairwise comparisons were 
corrected for multiple comparisons by using the Holm-Bonfer-
roni method (20). P values are denoted PHolm. An adjusted P value 
less than .05 was considered to indicate statistical significance.
Results
Study Participants
Twenty-six research sites participated in our study, with each 
site contributing up to 12 data sets. In total, data from 296 
healthy participants were collected (155 women and 141 men; 
mean age 6 standard deviation, 26 years 6 4.6; age inclusion 
range, 18–35 years). After visual inspection, three participants 
(examined by using Siemens scanners) were removed from fur-
ther analysis due to lipid contamination. There were no differ-
ences in sex (P = .69) of participants between the groups exam-
ined by using scanners from the different vendors. Participants 
examined by using Siemens scanners were older by approxi-
mately 2 years compared with those examined at GE (PHolm = 
.03) and Philips (PHolm = .005) sites. Demographic information 
on participants is given in the Table.
Figure 2: Graphs show average spectra from, A, GE Healthcare (Chicago, IL), B, Philips Healthcare (Best, the Netherlands), and, C, Siemens 
Healthineers (Erlangen, Germany) scanners with gray areas representing 61 standard deviation. Average LCModel (version 6.3–0D; Stephen 
Provencher, Oakville, Canada) fit results (red) and average residuals are shown for, D, the GE, E, the Philips, and, F, the Siemens scanners. Dashed 
line illustrates difference in methylene peak of creatine and phosphocreatine at 3.9 ppm that was partially suppressed by water suppression. Glx = 
glutamate and glutamine, NAA = N-acetylaspartate, mI = myo-inositol, MM = macromolecules, tCho = total choline, tCr = total creatine.
Považan et al
Radiology: Volume 295: Number 1—April 2020  n  radiology.rsna.org 175
Statistical Analysis
The vendor contribution to the total variance of the me-
tabolite concentrations ranged from 0% to 27%. The site-
related effects were more pronounced and found for all but 
phosphocholine (total cho-
line), and taurine and glucose. 
Also, due to substantial spectral 
overlap of glutamate and gluta-
mine (Glx) at 3.0 T, only their 
summed values (ie, Glx) are re-
ported (21). Thus, 14 metabo-
lites or metabolite sums were 
quantified. Mean CRLB of ala-
nine was above 50% and was 
therefore excluded from fur-
ther analysis. Eight metabolites 
were quantified in all partici-
pants, scyllo-inositol in 99.0% 
(290 of 293), phosphoethanol-
amine in 98.0% (287 of 293), 
g-aminobutyric acid in 95.9% 
(281 of 293), lactate in 94.9% 
(278 of 293), and ascorbate in 
81.9% (240 of 293) of all par-
ticipants (Table E2 [online]).
Metabolite ratios relative to 
tCr and their relative CRLBs 
are listed in Tables E3 and E4 
(online), and vendor-specific 
mean metabolite ratios com-
pared by site are shown in Fig-
ure 4. CRLBs were below 2% 
for tCr and total NAA and be-
low 5% for total choline, mI, 
and Glx across all sites and 
vendors (Table E4 [online]). 
Eleven of 13 metabolites ac-
quired with Siemens scanners, 
10 of 13 metabolites acquired 
with Philips scanners, and 
eight of 13 metabolites ac-
quired with GE scanners had 
site-specific mean and vendor-
specific mean CRLBs below 
20%.
Mean between-participant 
coefficients of variation (Table 
E5 [online]) and intersite coef-
ficients of variation (Table E2 
[online]) were below 10% for 
total choline/tCr, total NAA/
tCr, Glx/tCr, and mI/tCr. Be-
tween-participant coefficients 
of variation are compared 
against site-mean CRLBs in 
Figure 5. Four major metabo-
lite ratios (total choline/tCr, 
Glx/tCr, mI/tCr, and total NAA/tCr) showed substantially 
lower CRLBs (in the range of 1%–5%) compared with their 
corresponding between-participant coefficients of variation 
(range of 4%–15%).
Figure 3: Image shows example LCModel (version 6.3–0D; Stephen Provencher, Oakville, Canada) analysis with one 
spectrum, LCModel fit (red), spline baseline, residual, and individual macromolecule and metabolite contributions. Gray 
band highlights spectral region approximately 3.2 ppm, where signals of phosphoethanolamine (PE), myo-inositol (mI), 
glucose (Glc), taurine (Tau), glycerophosphocholine (GPC), and phosphocholine (PC) substantially overlap. Spectral fitting 
algorithm based on linear combination of model spectra as used in this study may be affected by this spectral overlap. This 
may introduce additional variability that is reflected on vendor level. Asc = ascorbate, Asp = aspartate, Cr = creatine, GABA 
= g-aminobutyric acid, Gln = glutamine, Glu = glutamate, GSH = glutathione, Lac = lactate, NAA = N-acetylaspartate, 
NAAG = N-acetylaspartylglutamate, PCr = phosphocreatine, sI = scyllo-inositol, CrCH2 = correction term for Cr, MM09 = 
macromolecule peak at 0.9 ppm, MM12 = macromolecule peak at 1.2 ppm, MM14 = macromolecule peak at 1.4 ppm, 
MM17 = macromolecule peak at 1.7 ppm, MM20 = macromolecule peaks at 2.0 ppm and 3.0 ppm, Lip13 = lipid peak 
at 1.3 ppm, Lip20 = lipid peaks at 2.0 ppm and 2.2 ppm and 2.8 ppm.
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differences were observed only for ascorbate/tCr (Pboot = .03) and 
total choline/tCr (Pboot = .003).
Discussion
We demonstrated that short-echo-time point-resolved spec-
troscopy (PRESS) MR spectroscopy of the human brain per-
formed at 3.0 T can quantify eight different metabolites in all 
293 participants based on the defined quality exclusion criteria 
in a 27-mL voxel and approximately 2-minute scan time. Our 
reported metabolite ratios are in agreement with previously 
published values (21–23). Uncertainty estimates (ie, Cramér-
Rao lower bounds [CRLBs]) of the major metabolites (ie, 
glutamate and glutamine [Glx], myo-inositol [mI], total cho-
line, total creatine [tCr], and total N-acetylaspartate [NAA]) 
were under 5% in all data sets, consistent with prior studies 
that have also reported less than 5% CRLBs for these com-
pounds at 3.0 T (24). Furthermore, despite no effort being 
made to standardize the acquisition beyond harmonization 
of relatively basic parameters (repetition time, echo time, voxel 
size, and scan time), there was no vendor effect observed for 
seven of the 12 metabolite-to-tCr ratios that were reported, 
including the major metabolites total NAA, Glx, and mI, as 
one metabolite (lactate; Pboot = .20) with site-level variance 
ranging from 3% up to 44% of total data variance. The re-
maining 50%–83% of the total variance was accounted for 
by interindividual differences, which included both actual 
biologic differences and participant-to-participant measure-
ment error.
Results of the linear mixed-effects modeling are summarized 
in Table E6 (online). The linear mixed-effects modeling showed 
the effects of vendor on total choline/tCr (Pboot , .001), g-
aminobutyric acid/tCr (Pboot , .001), phosphoethanolamine/
tCr (Pboot , .001), scyllo-inositol/tCr (Pboot = .03), and glucose 
and taurine/tCr (Pboot = .003) but not on mI/tCr (Pboot . .90), 
total NAA/tCr (Pboot = .13), Glx/tCr (Pboot = .11), ascorbate/tCr 
(Pboot = .08), aspartate/tCr (Pboot . .90), glutathione/tCr (Pboot . 
.90), or lactate/tCr (Pboot = .28). There was an effect of site on all 
metabolites (all Pboot , .02) except for lactate/tCr (Pboot = .20).
The conditional linear mixed-effects modeling showed an 
effect of SNR on ascorbate/tCr (Pboot , .001), glutathione/tCr 
(Pboot , .001), and mI/tCr (Pboot = .02) measures. Linewidth was 
related to aspartate/tCr (Pboot , .001), g-aminobutyric acid/tCr 
(Pboot , .001), glutathione/tCr (Pboot = .05), phosphoethanol-
amine/tCr (Pboot = .002), and Glx/tCr (Pboot = .007). No metabo-
lites showed an age effect except for lactate/tCr (Pboot = .007). Sex 
Figure 4: Graphs show metabolite ratios to total creatine (tCr) shown by site and vendor. Black lines represent mean, darker areas represent 95% confidence intervals, 
and tinted areas represent 61 standard deviation. Color-coded horizontal lines represent vendor-specific mean of plotted metabolite. A, Major metabolite signals: total 
N-acetylaspartate (NAA), total choline (tCho), myo-inositol (mI), and glutamate and glutamine (Glx) (plotted on range of 650% of their grand mean). B, Smaller signals: 
ascorbate (Asc), aspartate (Asp), g-aminobutyric acid (GABA), glucose (Glc) and taurine (Tau), glutathione (GSH), lactate (Lac), phosphoethanolamine (PE), and scyllo-
inositol (sI) (plotted on range of 6100% of their grand mean).
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signal (MM17). All these metabolites occur in a region of the 
spectrum (approximately 3.2 ppm to approximately 3.4 ppm) 
that is heavily overlapped with a number of multiplet signals. 
This vendor-level variability is, therefore, most likely driven by 
the ability of the spectral fitting algorithm to distinguish between 
these heavily overlapped resonances (25) and is influenced by the 
vendor-specific prior knowledge available, rather than by intrinsic 
well as ascorbate, aspartate, lactate, and glutathione among the 
smaller resonances.
Interestingly, there was a between-vendor difference of 16% 
for total choline, which is somewhat surprising given the lack of 
difference for the other major metabolite resonances. We found 
a vendor effect for four other metabolites (scyllo-inositol, phos-
phoethanolamine, glucose, and taurine) and one macromolecular 
Figure 5: Graphs show between-participant coefficient of variation plotted against site-mean Cramér-Rao lower bounds (CRLBs) (error of fitting) 
for reported metabolite ratios to total creatine (tCr) displayed for, A, four major metabolites with lower CRLBs: total N-acetylaspartate (tNAA), total 
choline (tCho), myo-inositol (mI), and glutamate and glutamine (Glx). B, Smaller signals with higher CRLBs. Black line is identity line. Color-coded by 
vendors. Asc = ascorbate, Asp = aspartate, GABA = g-aminobutyric acid, Glc = glucose, GSH = glutathione, Lac = lactate, PE = phosphoethanol-
amine, sI = scyllo-inositol, Tau = taurine.
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especially those from pericranial lipids that can complicate spec-
tral analysis. We had to exclude three data sets acquired by using 
Siemens scanners due to lipid contamination, two of which did 
not include use of such pulses.
Finally, CRLBs of the major metabolites were substantially 
lower compared with the between-participant coefficients of 
variation. This has previously been suggested to reflect the domi-
nance of interparticipant physiologic or measurement variance 
over the error in spectral fitting (17,30). Between-participant 
coefficients of variation and CRLBs were more similar for the 
lower-concentration metabolites. Thus, the contribution of the 
modeling error to between-participant differences cannot be ne-
glected for these compounds.
Our study had several limitations. It is likely that voxel posi-
tion varied slightly from participant to participant, because vox-
els were placed manually by different operators at each site. In 
addition, the introduction of a measured macromolecular spec-
trum into a spectral quantification (31,32) would potentially 
remove some of the fitting variability most notably within the 
range from 3–4 ppm, as the chosen macromolecular model does 
not cover this region.
In conclusion, our results are encouraging for the implemen-
tation of MR spectroscopy in large multisite studies of major 
metabolites using 3.0-T MR scanners from different vendors 
and also for allowing the quantitative comparison of spectra re-
corded at different sites (eg, for diagnostic purposes) to be more 
readily compared. Although single-site and single-vendor stud-
ies are ideal in minimizing variance of MR spectroscopy data, 
in many instances these are not feasible because it is impossible 
to recruit sufficient numbers of patients at individual sites. An 
ideal future study would image participants at all sites and might 
include imaging of a subset of volunteers across multiple sites to 
minimize between-participant variance while leaving between-
site and between-vendor variance to be investigated.
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between-vendor spectral differences per se. Consistent with this, 
resonances without substantial overlap (eg, macromolecules or lac-
tate) or those that have at least one dominant peak with minimal 
overlap (total NAA at 2.01 ppm, creatine and phosphocreatine at 
3.03 ppm, Glx at 3.75 ppm, and mI at 3.52 ppm) were less af-
fected by vendor-specific effects. Site-specific differences in meth-
odology were reflected in higher contribution of site effect in total 
variance of most metabolites, including the major metabolites that 
ranged from approximately 15% for total choline and mI up to 
approximately 44% for Glx. This effect needs to be considered 
in future multisite studies; however, it may be substantially mini-
mized by standardization of spectroscopic sequences.
Multiple technical factors influence the appearance and qual-
ity of brain MR spectra. Linewidths reflect the success of the 
shimming routine used, which was not standardized between 
sites in our study. Our relatively narrow and consistent line-
widths are similar to those reported in the literature (21,24). 
Our data suggest that the choice of shimming method does not 
influence results for the midparietal brain region (which is rela-
tively distant from magnetic susceptibility effects) (26). SNRs) 
depend on many factors, including radiofrequency coils used, 
voxel size, and pulse sequence efficiency. In our study, SNR was 
higher for Siemens scanners, which can be attributed to differ-
ences in how the width of the slice-selective pulses are defined by 
the vendors (27) (ie, the Siemens data were collected with larger 
actual voxel volumes compared with the other scanners, due to 
differences in the profiles of the slice selective pulses used for spa-
tial localization). Although linewidth and SNR have an impact 
on quantification accuracy and precision (28), SNR and line-
width were not major factors influencing the variance of our data 
because of the large voxel size and favorable brain region used.
Importantly, we customized our analyses for each vendor. 
LCModel basis sets were customized to account for between-
vendor differences in the PRESS sequence (ie, timing of the 
radiofrequency pulses and full spatial simulations of the refo-
cusing pulse profiles). Four sites equipped with GE scanners 
used PRESS sequences with slightly different interpulse tim-
ings, spectral bandwidth, and number of acquired points, so we 
created a separate basis set for these sites.
As was the case for the shimming routine, the method of water 
suppression was not standardized. A variety of water suppression 
modules are available (29), and different scanners used different 
approaches. In addition, the bandwidth of the water suppression 
pulses was not standardized, which influenced spectral appearance 
near the water peak. The mI peak at 4.05 ppm was suppressed by 
the water suppression pulses in data sets acquired by using GE 
scanners and partially in data sets acquired by using Philips scan-
ners. To a smaller extent, this effect was also observed with creatine 
and phosphocreatine at 3.9 ppm. To avoid this impacting spec-
tral quantitation, the 4.1-ppm mI peak was excluded from the 
LCModel analysis by limiting the spectral range to 0.5–4.0 ppm, 
and the correction term (CrCH2) was included in the basis set to 
account for effects on creatine and phosphocreatine at 3.9 ppm.
Outer-volume suppression pulses were implemented in com-
bination with PRESS localization on some scanners but not 
others. Outer-volume suppression helps to improve spatial local-
ization by suppressing unwanted signals from outside the voxel, 
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